When is disco cures cancer 2017

Burst Edition: Breyanzi lisocabtagene maraleucel FDA approval of Breyanzi lisocabtagene maraleucel for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma or DLBCL not otherwise specified including DLBCL arising from indolent lymphoma , high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.

Burst Edition: Tepmetko tepotinib and Ukoniq umbralisib FDA approvals of Tepmetko tepotinib for adult patients with metastatic non-small cell lung cancer or NSCLC harboring mesenchymal-epithelial transition or MET exon 14 skipping alterations and Ukoniq umbralisib for adult patients with relapsed or refractory marginal zone lymphoma who have received at least one prior anti-CDbased regimen and adult patients with relapsed or refractory follicular lymphoma who have received at least three prior lines of systemic therapy.

Burst Edition: Enhertu fam-trastuzumab deruxtecan-nxki and combination of Opdivo nivolumab and Cabometyx cabozantinib FDA approved fam-trastuzumab deruxtecan-nxki brand name Enhertu for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal adenocarcinoma who have received a prior trastuzumab-based regimen and combination of nivolumab brand name Opdivo and cabozantinib brand name Cabometyx as first-line treatment for patients with advanced renal cell carcinoma.

April 12, Run Time: Transcript. Burst Edition: Scemblix asciminib FDA approval of Scemblix asciminib for patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, previously treated with tyrosine kinase inhibitors, and for adult patients in chronic phase with the TI mutation. Burst Edition: Tecartus brexucabtagene autoleucel FDA approval of Tecartus brexucabtagene autoleucel for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Burst Edition:Tivdak tisotumab vedotin-tftv and Jakafi ruxolitinib FDA approvals of Tivdak tisotumab vedotin-tftv for adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy, and Jakafi ruxolitinib for chronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.

Burst Edition: Cabometyx cabozantinib FDA approval of Cabometyx cabozantinib for locally advanced or metastatic differentiated thyroid cancer. Burst Edition: Brukinsa zanubrutinib and Exkivity mobocertinib FDA approvals of Brukinsa zanubrutinib , for adult patients with relapsed or refractory marginal zone lymphoma, and Exkivity mobocertinib for adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations.

Burst Edition: Tibsovo ivosidenib FDA approval of Tibsovo ivosidenib for adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 mutation as detected by an FDA-approved test. Burst Edition: Jemperli dostarlimab-gxly and Opdivo nivolumab FDA approvals of Jemperli dostarlimab-gxly for patients with mismatch repair deficient recurrent or advanced solid tumors, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options, and Opdivo nivolumab for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence after undergoing radical resection.

Burst Edition: Welireg belzutifan FDA approval of Welireg belzutifan for adult patients with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring immediate surgery. Burst Edition: Lenvima lenvatinib in combination with Keytruda pembrolizumab FDA approval of Lenvima lenvatinib in combination with Keytruda pembrolizumab for first-line treatment of adult patients with advanced renal cell carcinoma.

Burst Edition: Keytruda pembrolizumab FDA approval of Keytruda pembrolizumab for high-risk early-stage triple-negative breast cancer.

Burst Edition: Keytruda pembrolizumab in combination with Lenvima lenvatinib FDA approval of Keytruda pembrolizumab in combination with Lenvima lenvatinib for advanced endometrial carcinoma. Cancer Res. Collins, A. A systematic review of the validity of patient derived xenograft PDX models: the implications for translational research and personalised medicine.

PeerJ 6 , e Kelland, L. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Cancer 40 , — Mosely, S. Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery. Cancer Immunol.

Dawson, D. A comparative assessment of the efficacy and side-effect liability of neuroprotective compounds in experimental stroke. Brain Res.

DeRose, Y. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes.

Tentler, J. Patient-derived tumour xenografts as models for oncology drug development. Clohessy, J. The mouse hospital and its integration in ultra-precision approaches to cancer care.

Front Oncol. Hidalgo, M. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Disco. Bertotti, A. Von Hoff, D. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. Patient-Derived Xenografts of breast cancer. Methods Mol. Fisher, T. Targeting of BB by monoclonal antibody PF enhances T-cell function and promotes anti-tumor activity. Simpson-Abelson, M. Lang, J. Capasso, A. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.

Cancer 7 , 37 Pauli, C. Personalized in vitro and in vivo cancer models to guide precision medicine. Que, Z. Establishment and characterization of a patient-derived circulating lung tumor cell line in vitro and in vivo. Cancer Cell Int. Lenos, K. Stem cell functionality is microenvironmentally defined during tumour expansion and therapy response in colon cancer. Cell Biol. Xu, H. Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine.

Neal, J. Organoid modeling of the tumor immune microenvironment. Prospective derivation of a living organoid biobank of colorectal cancer patients. Transplantation of engineered organoids enables rapid generation of metastatic mouse models of colorectal cancer.

Vlachogiannis, G. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science , — Van Dyke, T. Cancer modeling in the modern era: progress and challenges.

Singh, M. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Troiani, T. The use of xenograft models for the selection of cancer treatments with the EGFR as an example. Ideno N. A pipeline for rapidly generating genetically engineered mouse models of pancreatic cancer using in vivo CRISPR-Cas9-mediated somatic recombination.

Huijbers, I. Generating genetically modified mice: a decision guide. Koo, T. Oldrini, B. Spano, D. Molecular networks that regulate cancer metastasis. Semin Cancer Biol. Guan, X. Cancer metastases: challenges and opportunities. Acta Pharm. B 5 , — Anderson, R. A framework for the development of effective anti-metastatic agents. Johnstone, C. Functional and molecular characterisation of EO Enquist, I.

Lymph node-independent liver metastasis in a model of metastatic colorectal cancer. Gopinathan, A. GEMMs as preclinical models for testing pancreatic cancer therapies.

Morton, J. Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology , — Krepler, C.

A Comprehensive patient-derived xenograft collection representing the heterogeneity of melanoma. Cell Rep. Turajlic, S. Cell , — Jamal-Hanjani, M. PLoS Biol. Paul, S. Guerin, E. A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs. Cancer Res 73 , — Girotti, M. Kitz J. Circulating tumor cell analysis in preclinical mouse models of metastasis. Diagnostics Basel ; 8 Li, Q. Experimental animal modeling for immuno-oncology.

Fumagalli, A. A surgical orthotopic organoid transplantation approach in mice to visualize and study colorectal cancer progression. Rodriguez, E. Versatile and enhanced tumour modelling in mice via somatic cell transduction. Download references. The authors gratefully acknowledge the support of both Dr. Andy Harris and Mr. Anil Misra in critically evaluating this paper. Christopher R.

Ireson, Mo S. You can also search for this author in PubMed Google Scholar. Correspondence to Christopher R.

Jones is an employee of AstraZeneca. Professor Alan Palmer is a visiting professor at the University of Reading. The authors do not declare any other conflicts of interest.

Alavijeh, Ireson and Jones are funded directly by their employers. It may be especially helpful to groups disproportionately affected by financial toxicity, helping to achieve health equity. Trial registration: ClinicalTrials. Registered on February 23, Keywords: App-based intervention; Cancer treatment cost discussion; Financial toxicity; Patient active participation; Question prompt list; Randomized controlled trial.

Publication types Clinical Trial Protocol. Associated data ClinicalTrials.